News Articles Tagged: URAT1 Inhibitor

The Evolving Landscape of Gout Treatment: Insights into Verinurad (RDEA3170)

Explore how Verinurad (RDEA3170), a targeted URAT1 inhibitor, is shaping the future of gout and hyperuricemia treatment by focusing on uric acid excretion.

Understanding Verinurad (CAS 1352792-74-5): A Key Player in Urate Transporter Inhibition

Get acquainted with Verinurad (CAS 1352792-74-5), a crucial URAT1 inhibitor, and its role in pharmaceutical research for metabolic disorders like gout and hyperuricemia.

The Pharmaceutical Journey of Verinurad (RDEA3170): From Discovery to Clinical Trials

Trace the development path of Verinurad (RDEA3170), a crucial URAT1 inhibitor, highlighting its discovery, mechanism, and progression through clinical trials for gout and hyperuricemia.

Advancements in Hyperuricemia Treatment: The Science Behind Verinurad

Delve into the scientific basis of Verinurad (RDEA3170), a cutting-edge URAT1 inhibitor designed to combat hyperuricemia and its associated health risks. Explore its efficacy and target.